Drugs /
dactinomycin
Overview
Clinical Trials
Dactinomycin has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating dactinomycin, 3 are phase 2 (3 open) and 2 are phase 3 (2 open).
PAX3-FOXO1 Fusion is the most frequent biomarker inclusion criterion for dactinomycin clinical trials.
Alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, and rhabdomyosarcoma are the most common diseases being investigated in dactinomycin clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.